N⁶-Methyladenosine-Modified ATP8B1-AS1 Exerts Oncogenic Roles in Hepatocellular Carcinoma via Epigenetically Activating MYC

References

• Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109. doi:10.1093/jnci/djx030
   Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Baretti M, Kim AK, Anders RA. Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell. 2022;40:252–254. doi:10.1016/j.ccell.2022.02.017
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232. doi:10.1038/s41590-018-0044-z
   PubMed Web of Science ®Google Scholar
• Zhou G, Boor PPC, Bruno MJ, Sprengers D, Kwekkeboom J. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. Br J Cancer. 2022;126:10–23. doi:10.1038/s41416-021-01453-3
   PubMed Web of Science ®Google Scholar
• Hajiev S, Allara E, Motedaysmallie CAL, et al. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. Br J Cancer. 2021;124:407–413. doi:10.1038/s41416-020-01116-9
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184:404–421 e16. doi:10.1016/j.cell.2020.11.041
   PubMed Web of Science ®Google Scholar
• You H, Zhang N, Yu T, et al. Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis. Br J Cancer. 2023;128:992–1004. doi:10.1038/s41416-022-02115-8
   PubMed Web of Science ®Google Scholar
• Li J, Li MH, Wang TT, et al. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/beta-catenin/MYC/HMGCS2 axis. Br J Cancer. 2021;125:865–876. doi:10.1038/s41416-021-01490-y
   PubMed Web of Science ®Google Scholar
• Xu Q, Liao Z, Gong Z, et al. Down-regulation of EVA1A by miR-103a-3p promotes hepatocellular carcinoma cells proliferation and migration. Cell Mol Biol Lett. 2022;27:93. doi:10.1186/s11658-022-00388-8
   PubMed Web of Science ®Google Scholar
• Wen J, Huang Z, Wei Y, et al. Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling. Cell Mol Biol Lett. 2022;27:79. doi:10.1186/s11658-022-00370-4
   PubMed Web of Science ®Google Scholar
• Xing Y, Liu Y, Qi Z, Liu Z, Wang X, Zhang H. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway. Cell Mol Biol Lett. 2021;26:49. doi:10.1186/s11658-021-00295-4
   PubMed Web of Science ®Google Scholar
• Yan W, Han Q, Gong L, et al. MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2. Br J Cancer. 2022;127:612–623. doi:10.1038/s41416-022-01831-5
   PubMed Web of Science ®Google Scholar
• Zhao W, Mo H, Liu R, Chen T, Yang N, Liu Z. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression. Br J Cancer. 2022;127:202–210. doi:10.1038/s41416-022-01784-9
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu X, Qi M, et al. N(6)-methyladenosine regulates maternal RNA maintenance in oocytes and timely RNA decay during mouse maternal-to-zygotic transition. Nat Cell Biol. 2022;24:917–927. doi:10.1038/s41556-022-00915-x
   PubMed Web of Science ®Google Scholar
• Tang Q, Li L, Wang Y, et al. RNA modifications in cancer. Br J Cancer. 2023;2023:1. doi:10.1038/s41416-023-02275-1
   Google Scholar
• Ito-Kureha T, Leoni C, Borland K, et al. The function of Wtap in N(6)-adenosine methylation of mRNAs controls T cell receptor signaling and survival of T cells. Nat Immunol. 2022;23:1208–1221. doi:10.1038/s41590-022-01268-1
   PubMed Web of Science ®Google Scholar
• Cai Z, Zhang Y, Yang L, et al. ALKBH5 in mouse testicular Sertoli cells regulates Cdh2 mRNA translation to maintain blood-testis barrier integrity. Cell Mol Biol Lett. 2022;27:101. doi:10.1186/s11658-022-00404-x
   PubMed Web of Science ®Google Scholar
• Zhang R, Qu Y, Ji Z, et al. METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner. Cell Mol Biol Lett. 2022;27:55. doi:10.1186/s11658-022-00349-1
   PubMed Web of Science ®Google Scholar
• Sun Z, Hong Q, Liu Y, et al. Oviduct transcriptomic reveals the regulation of mRNAs and lncRNAs related to goat prolificacy in the luteal phase. Animals. 2022;12. doi:10.3390/ani12202823
   Web of Science ®Google Scholar
• Paramasivam A, Priyadharsini JV. RNA N6-methyladenosine: a new player in autophagy-mediated anti-cancer drug resistance. Br J Cancer. 2021;124:1621–1622. doi:10.1038/s41416-021-01314-z
   PubMed Web of Science ®Google Scholar
• Weng H, Huang F, Yu Z, et al. The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40:1566–1582 e10. doi:10.1016/j.ccell.2022.10.004
   PubMed Web of Science ®Google Scholar
• Lan J, Xu B, Shi X, Pan Q, Tao Q. WTAP-mediated N(6)-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy. Cell Mol Biol Lett. 2022;27:51. doi:10.1186/s11658-022-00350-8
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xie W, Pickering BF, et al. N(6)-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell. 2021;39:958–972 e8. doi:10.1016/j.ccell.2021.04.017
   PubMed Web of Science ®Google Scholar
• Yuan JH, Yang F, Wang F, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–681. doi:10.1016/j.ccr.2014.03.010
   PubMed Web of Science ®Google Scholar
• Unfried JP, Ulitsky I. Substoichiometric action of long noncoding RNAs. Nat Cell Biol. 2022;24:608–615. doi:10.1038/s41556-022-00911-1
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang Q, Li J, et al. KCNQ1OT1 promotes genome-wide transposon repression by guiding RNA-DNA triplexes and HP1 binding. Nat Cell Biol. 2022;24:1617–1629. doi:10.1038/s41556-022-01008-5
   PubMed Web of Science ®Google Scholar
• de Jong JJ, Valderrama BP, Perera J, et al. Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis. Br J Cancer. 2022;127:313–320. doi:10.1038/s41416-022-01799-2
   PubMed Web of Science ®Google Scholar
• Yuan JH, Liu XN, Wang TT, et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol. 2017;19:820–832. doi:10.1038/ncb3538
   PubMed Web of Science ®Google Scholar
• Li Y, Ding T, Hu H, et al. LncRNA-ATB participates in the regulation of calcium oxalate crystal-induced renal injury by sponging the miR-200 family. Mol Med. 2021;27:143. doi:10.1186/s10020-021-00403-2
   PubMed Web of Science ®Google Scholar
• Li G, Kryczek I, Nam J, et al. LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021;23:526–537. doi:10.1038/s41556-021-00672-3
   PubMed Web of Science ®Google Scholar
• Ouyang J, Zhong Y, Zhang Y, et al. Long non-coding RNAs are involved in alternative splicing and promote cancer progression. Br J Cancer. 2022;126:1113–1124. doi:10.1038/s41416-021-01600-w
   PubMed Web of Science ®Google Scholar
• Li R, Wang X, Zhu C, Wang K. lncRNA PVT1: a novel oncogene in multiple cancers. Cell Mol Biol Lett. 2022;27:84. doi:10.1186/s11658-022-00385-x
   PubMed Web of Science ®Google Scholar
• Wang X, Song Y, Shi Y, Yang D, Li J, Yin B. SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells. Cell Mol Biol Lett. 2022;27:13. doi:10.1186/s11658-022-00313-z
   PubMed Web of Science ®Google Scholar
• Zhou Z, Cao Y, Yang Y, Wang S, Chen F. METTL3-mediated m(6)A modification of lnc KCNQ1OT1 promotes doxorubicin resistance in breast cancer by regulating miR-103a-3p/MDR1 axis. Epigenetics. 2023;18:2217033. doi:10.1080/15592294.2023.2217033
   PubMed Web of Science ®Google Scholar
• Dai YZ, Liu YD, Li J, et al. METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m(6)A-dependent manner. Cell Mol Biol Lett. 2022;27:41. doi:10.1186/s11658-022-00342-8
   PubMed Web of Science ®Google Scholar
• Wu X, Deng Z, Liao X, et al. Establishment of prognostic signatures of N6-methyladenosine-related lncRNAs and their potential functions in hepatocellular carcinoma patients. Front Oncol. 2022;12:865917. doi:10.3389/fonc.2022.865917
   PubMed Web of Science ®Google Scholar
• Lin Y, Xiao Y, Liu S, Hong L, Shao L, Wu J. Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer. BMC Med Genomics. 2022;15:221. doi:10.1186/s12920-022-01369-8
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang Y, Yao H, et al. MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation. J Exp Clin Cancer Res. 2022;41:337. doi:10.1186/s13046-022-02547-3
   PubMed Web of Science ®Google Scholar
• Xiao Y, Wang Y, Tang Q, Wei L, Zhang X, Jia G. An elongation- and ligation-based qPCR amplification method for the radiolabeling-free detection of locus-specific N(6) -methyladenosine modification. Angew Chem Int Ed Engl. 2018;57:15995–16000. doi:10.1002/anie.201807942
   PubMed Web of Science ®Google Scholar
• Liu XN, Yuan JH, Wang TT, Pan W, Sun SH. An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression. Biomed Pharmacother. 2017;89:276–283. doi:10.1016/j.biopha.2017.01.139
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69:7385–7392. doi:10.1158/0008-5472.CAN-09-1089
   PubMed Web of Science ®Google Scholar
• Li Y, Xia L, Tan K, et al. N(6)-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat Genet. 2020;52:870–877. doi:10.1038/s41588-020-0677-3
   PubMed Web of Science ®Google Scholar
• Methot SP, Padeken J, Brancati G, et al. H3K9me selectively blocks transcription factor activity and ensures differentiated tissue integrity. Nat Cell Biol. 2021;23:1163–1175. doi:10.1038/s41556-021-00776-w
   PubMed Web of Science ®Google Scholar
• Farzaneh M, Ghasemian M, Ghaedrahmati F, et al. Functional roles of lncRNA-TUG1 in hepatocellular carcinoma. Life Sci. 2022;308:120974. doi:10.1016/j.lfs.2022.120974
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang F, Yuan JH, et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis. 2013;34:577–586. doi:10.1093/carcin/bgs381
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhou H, Xie J, Zhang H, Shen X, Zhu D. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs. J Thorac Dis. 2022;14:4828–4845. doi:10.21037/jtd-22-1534
   PubMed Web of Science ®Google Scholar
• Zhu XT, Yuan JH, Zhu TT, Li YY, Cheng XY. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3. FEBS J. 2016;283:3739–3754. doi:10.1111/febs.13839
   PubMed Web of Science ®Google Scholar
• Xia A, Yuan W, Wang Q, et al. The cancer-testis lncRNA lnc-CTHCC promotes hepatocellular carcinogenesis by binding hnRNP K and activating YAP1 transcription. Nat Cancer. 2022;3:203–218. doi:10.1038/s43018-021-00315-4
   PubMedGoogle Scholar
• DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res. 2017;2:129–136. doi:10.1016/j.ncrna.2017.11.001
   PubMedGoogle Scholar
• Wang J, Xiang J, Li X. Construction of a competitive endogenous RNA network for pancreatic adenocarcinoma based on weighted gene co-expression network analysis and a prognosis model. Front Bioeng Biotechnol. 2020;8:515. doi:10.3389/fbioe.2020.00515
   PubMed Web of Science ®Google Scholar
• Su X, Malouf GG, Chen Y, et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget. 2014;5:9864–9876. doi:10.18632/oncotarget.2454
   PubMedGoogle Scholar
• Diao MN, Zhang XJ, Zhang YF. The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy. Br J Cancer. 2023;2023:1–6. doi:10.1038/s41416-023-02246-6
   Google Scholar
• Shimura T, Kandimalla R, Okugawa Y, et al. Novel evidence for m(6)A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer. Br J Cancer. 2022;126:228–237. doi:10.1038/s41416-021-01581-w
   PubMed Web of Science ®Google Scholar